Randomized phase 2 study: Elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, Javier de la Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob P. Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K. Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying Ming Jou, Michael Robbins, Giuseppe Antonio Palumbo

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Randomized phase 2 study: Elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences